Increased anxiety 3 months after brief exposure to MDMA ('Ecstasy') in rats: Association with altered 5-HT transporter and receptor density

Neuropsychopharmacology

Volumn 28, Issue 8, 2003, Pages 1472-1484

  McGregor, Iain S ^a   Clemens, Kelly J ^a   Van Der Plasse, Geoffrey ^a   Li, Kong M ^b   Hunt, Glenn E ^a   Chen, Feng ^c   Lawrence, Andrew J ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

5 HT; Anxiety; Autoradiography; Ecstasy; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; SEROTONIN; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CARRIER PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, RAT;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BRAIN CORTEX; CORPUS STRIATUM; DRUG DOSE REGIMEN; HIPPOCAMPUS; HYPOTHALAMUS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PYRIFORM CORTEX; RAT; RAT STRAIN; RECEPTOR DENSITY; SOCIAL INTERACTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MALE; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; TIME; WISTAR RAT;

ANIMALS; ANXIETY; CARRIER PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS;

EID: 0042887027     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300185     Document Type: Article

References (82)

1. 1A receptor density and 8-OH-DPAT-induced hypothermia - blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol 346: 181-188.
2. 1A receptors in rats. Eur J Pharmacol 281: 101-105.
3. 2 receptors. Neuropsychopharmacology 26: 40-52.
4. Battaglia G, Sharkey J, Kuhar MJ, De Souza EB (1991). Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse 8: 249-260.
5. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987). 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3h]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911-916.
6. Boot BP, McGregor LS, Hall W (2000). MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355: 1818-1821.
7. Boot BP, Mechan AO, McCann UD, Ricaurte G (2002). MDMA-and P-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol 453: 239-244.
8. Broening HW, Bowyer JF, Slikker W (1995). Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275: 325-333.
9. Callahan BT, Cord BJ, Ricaurte GA (2001). Long-term impairment of anterograde axonal transport along fiber projection originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40: 113-121.
10. 1B agonist. J Pharmacol Exp Ther 263: 318-326.
11. 3 receptors in fawn-hooded rats: a quantitative autoradiography study. Alcoholism: Clin Exp Res 24: 1093-1102.
12. 1B receptor in dorsal raphe nucleus using herpes simplex virus gene transfer increases anxiety behavior after inescapable stress. J Neurosci 22: 4550-4562.
13. Clement Y, Kia KH, Daval G, Verge D (1996). An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Brain Res 709: 229-242.
14. Colado MI, O'Shea E, Esteban B, Green AR (2001). Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ('Ecstasy')-induced neurodegeneration in rat brain. Psychopharmacology 157: 82-88.
15. Colado MI, Williams JL, Green AR (1995). The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115: 1281-1289.
16. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987). Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345.
17. 2A/2C receptor binding sites in the rat cerebral cortex. Brain Res 795: 264-276.
18. 2A/2C binding sites in adult rat basal ganglia following lesions of serotonergic neurons. Brain Res 793: 103-111.
19. Darvesh AS, Shankaran M, Gudelsky GA (2002). 3,4- Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J Pharmacol Exp Ther 301: 138-144.
20. Dielenberg RA, Hunt GE, McGregor IS (2001). 'When a rat smells a cat': the distribution of c-fos expression in the rat brain following exposure to a predatory odor. Neuroscience 104: 1085-1097.
21. File SE, Gonzalez LE, Gallant R (1999). Role of the dorsomedial hypothalamus in mediating the response to benzodiazepines on trial 2 in the elevated plus-maze test of anxiety. Neuropsychopharmacology 21: 312-320.
22. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995). Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). J Neurosci 15: 5476-5485.
23. Fitzgerald RL, Blanke RV, Poklis A (1990). Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Chirality 2: 241-248.
24. Fone KCF, Beckett SRG, Topham IA, Swettenham J, Ball M, Maddocks L (2002). Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159: 437-444.
25. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT et al (2002). The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135: 649-656.
26. Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000). Mood state and brain electric activity in Ecstasy users. NeuroReport 11: 157-162.
27. 1A serotonin agonist 8-hydroxy-2-(di-n-propylamino)-tetralin. Pharmacol Biochem Behav 66: 483-488.
28. 1A receptor agonist (+/-)-8-hydroxy-(di-n-propylamino) tetralin. Neuropsychobiology 43: 42-48.
29. Green AR, McGregor IS (2002). On the long-term increase in anxiety following central serotonin depletion with MDMA ('Ecstasy'). Psychopharmacology 162: 448-450.
30. Griebel G (1995). 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65: 319-395.
31. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36: 793-802.
32. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS (2002). Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 446: 89-96.
33. Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE (2001). Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sci 68: 1367-1382.
34. Hebert C, Habimana A, Elie R, Reader TA (2001). Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study. Neurochem Int 38: 63-74.
35. Jagust WJ, Eberling JL, Biegon A, Taylor SE, Vanbrocklin HF, Jordan S et al (1996). Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. J Nucl Med 37: 1207-1214.
36. 2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15: 116-124.
37. 2C receptor antagonist. Neuropharmacology 36: 609-620.
38. Kish SJ (2002). How strong is the evidence that brain serotonin neurons are damaged in human users of Ecstasy. Pharmacol Biochem Behav 71: 845-855.
39. 1A receptor and 5-HT transporter ligands in rat cortex and hippocampus following cholinergic and serotonergic lesions. Brain Res 612: 326-329.
40. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
41. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS (1996). Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. PART II: radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276: 855-865.
42. Malberg JE, Sabol KE, Seiden LS (1996). Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278: 258-267.
43. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094.
44. 1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. J Neurosci 19: 6157-6168.
45. 2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 71: 615-625.
46. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999). Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147: 56-65.
47. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998). Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
48. MeChan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') to rats. Br J Pharmacol 135: 170-180.
49. MeChan AO, O'Shea E, Elliott JM, Colado MI, Green AR (2001). A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) to rats results in a long term defect in thermoregulation. Psychopharmacology 155: 413-418.
50. Morgan MJ (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152: 230-248.
51. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001). Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ('Ecstasy'). Eur J Pharmacol 433: 91-99.
52. 1b receptors in the brain of the rat. J Pharmacol Exp Ther 244: 144-153.
53. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998). The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (Ecstasy). Neuropharmacology 37: 919-926.
54. Parrott AC (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16: 557-577.
55. Parrott AC, Sisk E, Turner JJD (2000). Psychobiological problems in heavy 'Ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110.
56. Paxinos G, Watson C (1997). The Rat Brain In Stereotaxic Co-Ordinates, (Compact 3rd edn). Academic Press: Academic Press.
57. Ramboz S, Ousting R, Amara DA, Kung HF, Blier P, Mendelsohn M et al (1998). Serotonin receptor IA knockout - an animal model of anxiety-related disorder. Proc Natl Acad Sci 95: 14476-14481.
58. Rausch JL, Hobby HM, Shendarkar N, Johnson ME, Li J (2001). Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. J Clin Psychopharmacol 21: 139-142.
59. Reneman L, Booij J, Lavalaye J, De Bruin K, Reitsma JB, Gunning B et al (2002a). Use of amphetamine by recreational users of Ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [23i]beta-CIT SPECT study-preliminary report. Psychopharmacology 159: 335-340.
60. Reneman L, Booij J, Schmand B, Van Den Brink W, Gunning B (2000). Memory disturbances in 'Ecstasy' users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 148: 322-324.
61. 2A receptors in rat and human brain. Neuropsychopharmacology 26: 387-396.
62. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986-988.
63. Ricaurte G, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002). Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ('Ecstasy'). Science 297: 2260-2263.
64. Sabol KE, Lew R, Richards JB, Vosmer GL, Seiden LS (1996). Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 276: 846-854.
65. 1B receptor. Science 265: 1875-1878.
66. Scallet AC, Lipe GW, Ali SF, Holson RR, Frith CH, Slikker Jr W (1988). Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine. Neurotoxicology 9: 529-537.
67. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993). Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264: 1484-1491.
68. 1B receptor. Psychopharmacology 141: 154-161.
69. 2 receptors. Neuropharmacology 31: 881-893.
70. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT et al (1998). In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse 29: 183-192.
71. Schifano F, Difuria L, Forza C, Minicuci N, Bricolo R (1998). MDMA (Ecstasy) consumption in the context of polydrug abuse - a report on 150 patients. Drug Alcohol Depend 52: 85-90.
72. 2 receptors. Brain Res 529: 85-90.
73. Schworer H, Racke K, Kilbinger H (1987). Cholinergic modulation of the release of 5-hydroxytryptamine from the guinea pig ileum. Naunyn-Schmieddebergs Arch Pharmacol 336: 127-132.
74. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999). Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('Ecstasy') users. Br J Psychiatry 175: 63-69.
75. 1B MRNA in rat brain. Mol Psychiatry 4: 572-579.
76. Shekhar A, Katner JS (1995). Dorsomedial hypothalamic GABA regulates anxiety in the social interaction test. Pharmacol Biochem Behav 50: 253-258.
77. 2C receptor mutant mice. Proc Natl Acad Sci 95: 15026-15031.
78. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
79. Verge D, Daval G, Marcinkiewicz M, Patey A, El Mestikawy S, Gozlan H et al (1986). Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci 6: 3474-3482.
80. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, De Visser S, Kuijpers M et al (2001). Cognitive performance and serotonergic function in users of Ecstasy. Psychopharmacology 153: 196-202.
81. Wareing M, Fisk JE, Murphy PN (2000). Working memory deficits in current and previous users of MDMA ('Ecstasy'). Br J Psychol 91: 181-188.
82. 1B receptors. Neuropsychopharmacology 21: S52-S60.